Loudon Investment Management LLC Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Loudon Investment Management LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 12,685 shares of the biopharmaceutical company’s stock, valued at approximately $355,000.

Several other large investors have also recently bought and sold shares of the company. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer in the second quarter valued at $29,000. Creekmur Asset Management LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new position in Pfizer during the second quarter valued at approximately $34,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, August 19th. Barclays raised their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Up 0.2 %

Shares of NYSE PFE traded up $0.05 on Friday, reaching $28.56. 31,214,484 shares of the company’s stock traded hands, compared to its average volume of 38,328,773. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business’s 50 day simple moving average is $29.06 and its two-hundred day simple moving average is $28.05. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.64. The company has a market cap of $161.84 billion, a price-to-earnings ratio of -476.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the previous year, the business posted $0.67 EPS. Pfizer’s revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.88%. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.